Medical Specialty >> OncologyRead article
- Tighter Rules on Arsenic in Water Saved Lives: Study
- Medical Marijuana Won’t Help Most Sick Kids
- Textured Breast Implants Linked to Rare Cancer
- How Many Mutant Genes Drive Cancer?
- Limited Evidence of Benefit for Medical Cannabinoids in Children
- Leukemia Patients Who Survive Severe GVHD Often Fare Worse
- Clinician Job Satisfaction Linked to Improved Burnout Scores
Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of… Elizabeth M. Swisher, MD. Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity… Bert Vogelstein, MD. Investigators at Johns Hopkins University in Baltimore used complex mathematical modeling to track mutations driving abnormal cell growth for 32 types of cancer. From their calculations, the researchers believe that the bulk of cancers are caused by random DNA copying errors (replicative mutations).…
The BRCA gene test is used to identify mutations in either one of the two breast cancer susceptibility genes, BRCA1 and BRCA2. Women who have inherited…
Thank you for reading my article. Interesting theory. Lots of research is ongoing to figure out the many ways aspirin does it magic.